AstraZeneca bags another cancer drug deal, this time with Inovio

A sign is seen at an AstraZeneca site in MacclesfieldAstraZeneca has clinched its third deal in less than a week to bolster its strategically important cancer drug pipeline by signing up rights to an experimental immune system-boosting medicine from Inovio Pharmaceuticals. Inovio will get $ 27.5 million upfront and potential future payments of up to $ 700 million, depending on the success of its INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. AstraZeneca said on Monday its MedImmune biotech unit would study INO-3112 in combination with other immunotherapy drugs.



Sexual Health News Headlines – Yahoo! News